Regeneron stock crashes on COPD data: here’s why I’m buying REGN today

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) crashed more than 15% this morning on disappointing data from Phase 3 trials of its experimental drug itepekimab. Itepekimab is a drug candidate for chronic…